Showing papers by "Per Anton Sirnes published in 2012"
••
TL;DR: A prospective, randomized, double blind, Active-controlled, superiority study of Vernakalant vs. amiodarone in Recent Onset atrial fibrillation for the prevention of cardiovascular Hospitalization or death from any cause.
Abstract: ACCF
: American College of Cardiology Foundation
ACCP
: American College of Chest Physicians
ACS
: acute coronary syndrome
ACT
: Atrial arrhythmia Conversion Trial
ADONIS
: American–Australian–African trial with DronedarONe In atrial fibrillation or flutter for the maintenance of Sinus rhythm
AF
: atrial fibrillation
AHA
: American Heart Association
ANDROMEDA
: ANtiarrhythmic trial with DROnedarone in Moderate-to-severe congestive heart failure Evaluating morbidity DecreAse
APHRS
: Asia Pacific Heart Rhythm Society
aPTT
: activated partial thromboplastin time
ARB
: angiotensin-receptor blocker
ARISTOTLE
: Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation
ATHENA
: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter
ATRIA
: AnTicoagulation and Risk factors In Atrial fibrillation
AVERROES
: Apixaban VErsus acetylsalicylic acid (ASA) to Reduce the Rate Of Embolic Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
AVRO
: A prospective, randomized, double-blind, Active-controlled, superiority study of Vernakalant vs. amiodarone in Recent Onset atrial fibrillation
b.i.d
: bis in die (twice daily)
b.p.m.
: beats per minute
CABANA
: Catheter ABlation vs . ANtiarrhythmic drug therapy for Atrial fibrillation
CABG
: coronary artery bypass graft
CAP
: Continued Access to Protect AF
CHA2DS2-VASc
: Congestive heart failure or left ventricular dysfunction Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
CHADS2
: Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled)
CI
: confidence interval
CRAFT
: Controlled Randomized Atrial Fibrillation Trial
CrCl
: creatinine clearance
DAFNE
: Dronedarone Atrial FibrillatioN study after Electrical cardioversion
DIONYSOS
: Randomized Double blind trIal to evaluate efficacy and safety of drOnedarone (400 mg b.i.d.) vs . amiodaroNe (600 mg q.d. for 28 daYS, then 200 mg qd thereafter) for at least 6 mOnths for the maintenance of Sinus rhythm in patients with atrial fibrillation
EAST
: Early treatment of Atrial fibrillation for Stroke prevention Trial
EHRA
: European Heart Rhythm Association
ECG
: electrocardiogram
EMA
: European Medicines Agency
ERATO
: Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation
EURIDIS
: EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm
FAST
: atrial Fibrillation catheter Ablation vs . Surgical ablation Treatment
FDA
: Food and Drug Administration
Flec-SL
: Flecainide Short-Long trial
HAS-BLED
: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly
HF-PEF
: heart failure with preserved ejection fraction
HF-REF
: heart failure with reduced ejection fraction
HR
: hazard ratio
HRS
: Heart Rhythm Society
ICH
: intracranial haemorrhage
INR
: international normalized ratio
i.v.
: intravenous
J-RHYTHM
: Japanese RHYTHM management trial for atrial fibrillation
LAA
: left atrial appendage
LoE
: level of evidence
LVEF
: left ventricular ejection fraction
MANTRA-PAF
: Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation
NICE
: National Institute for Health and Clinical Excellence
NOAC
: novel oral anticoagulant
NSAID
: non-steroidal anti-inflammatory drug
NYHA
: New York Heart Association
OAC
: oral anticoagulant or oral anticoagulation
o.d.
: omni die (every day)
PALLAS
: Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy
PCI
: percutaneous coronary intervention
PREVAIL
: Prospective Randomized EVAluation of the LAA closure device In patients with atrial fibrillation v s. Long-term warfarin therapy
PROTECT AF
: WATCHMAN LAA system for embolic PROTECTion in patients with Atrial Fibrillation
PT
: prothrombin time
RAAFT
: Radio frequency Ablation Atrial Fibrillation Trial
RE-LY
: Randomized Evaluation of Long-term anticoagulant therapY with dabigatran etexilate
ROCKET-AF
: Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in atrial fibrillation
RRR
: relative risk reduction
TE
: thromboembolism
TIA
: transient ischaemic attack
t.i.d.
: ter in die (three times daily)
TOE
: transoesophageal echocardiogram
TTR
: time in therapeutic range
VKA
: vitamin K antagonist
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on …
3,272 citations
••
TL;DR: Authors/Task Force Members: John J. McMurray (Chairperson) (UK), Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Angelo Auricchio (Switzerland), Michael Bohm ( Germany), Kenneth Dickstein (Norway), Volkmar Falk (Sw Switzerland), Gerasimos Filippatos (G Greece), Cândida Fonseca (Portugal), Miguel Angel Gomez-Sanchez (Spain).
Abstract: The originally published version of this paper was incorrect. In the table on page 1816, the Class of recommendation and Level of evidence for ‘The patient is pacemaker dependent as a result of AV nodal ablation’ should have read ‘IIa’ and ‘B’ respectively.
Appendix: six tables ([3][1
2,627 citations
••
413 citations
•
TL;DR: Authors/Task Force Members: Alec Vahanian (Chairperson) (France)*, Ottavio Alfieri (Chair person)* ( Italy), Felicita Andreotti (Italy), Manuel J. Antunes (Portugal), Gonzalo Barón-Esquivias (Spain)
Abstract: Authors/Task Force Members: Alec Vahanian (Chairperson) (France)*, Ottavio Alfieri (Chairperson)* (Italy), Felicita Andreotti (Italy), Manuel J. Antunes (Portugal), Gonzalo Barón-Esquivias (Spain), Helmut Baumgartner (Germany), Michael Andrew Borger (Germany), Thierry P. Carrel (Switzerland), Michele De Bonis (Italy), Arturo Evangelista (Spain), Volkmar Falk (Switzerland), Bernard Iung (France), Patrizio Lancellotti (Belgium), Luc Pierard (Belgium), Susanna Price (UK), Hans-Joachim Schäfers (Germany), Gerhard Schuler (Germany), Janina Stepinska (Poland), Karl Swedberg (Sweden), Johanna Takkenberg (The Netherlands), Ulrich Otto Von Oppell (UK), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain), Marian Zembala (Poland)
123 citations